On October 15, 2026, AstraZeneca announced a strategic drug discovery collaboration and license agreement with AI drug discovery company insitro. insitro will use its Virtual Human platform to identify causal disease biology in MASH and cardiomyopathy and advance AstraZeneca-nominated targets to development candidate stage. AstraZeneca will pay $40 million upfront, up to approximately $1.46 billion in milestones, with total potential value of about $1.5 billion plus tiered royalties on global sales.